Stock Scorer

Ionis Pharmaceuticals Inc (IONS)

Ionis Pharmaceuticals Inc reported revenue of 267.9M USD for the quarter ending 30 June 2026, down 40.7% from 452M a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q2 '26 · ending 30 June 2026 267.9M -40.7%
Gross Profit Q2 '26 · ending 30 June 2026 265.2M -40.8%
Operating Income Q2 '26 · ending 30 June 2026 -102.3M -173.2%
Net Income Q2 '26 · ending 30 June 2026 -114.6M -192.8%
Cost of Revenue Q2 '26 · ending 30 June 2026 2.7M -34.0%
Operating Cash Flow Q2 '26 · ending 30 June 2026 565.5M +273.7%
Free Cash Flow Q2 '26 · ending 30 June 2026 549.5M +295.2%
Shares Outstanding Q2 '26 · ending 30 June 2026 165.4M +4.2%
EPS Q2 '26 · ending 30 June 2026 -3.46 —

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-12-31 943.7M-381.7M-381.4M-320M
20242024-12-31 705.1M-475.1M-453.9M-546.2M
20232023-12-31 787.6M-353.7M-366.3M-331.3M
20222022-12-31 587.4M-410.2M-269.7M-290.1M
20212021-12-31 810.5M-30.2M-28.6M18.8M
20202020-12-31 729.3M-172.1M-444.3M772K
20192019-12-31 1.1B365.9M278.1M314.7M
20182018-12-31 599.7M-61.4M273.7M589.3M
20172017-12-31 514.2M31M346K139.4M
20162016-12-31 372.8M-20.2M-60.4M-119.2M

Every period

Revenue Quarterly

PeriodEndingRevenue
Q2 '262026-06-30267.9M
Q1 '262026-03-31246.1M
Q4 '252025-12-31203.3M
Q3 '252025-09-30156.7M
Q2 '252025-06-30452M
Q1 '252025-03-31131.6M
Q4 '242024-12-31226.6M
Q3 '242024-09-30133.8M
Q2 '242024-06-30225.2M
Q1 '242024-03-31119.5M
Q4 '232023-12-31324.5M
Q3 '232023-09-30144.2M
Q2 '232023-06-30188.4M
Q1 '232023-03-31130.5M
Q4 '222022-12-31151.9M
Q3 '222022-09-30159.8M
Q2 '222022-06-30133.8M
Q1 '222022-03-31141.9M
Q4 '212021-12-31440M
Q3 '212021-09-30133.1M

Gross Profit Quarterly

Revenue minus cost of sales. This filer tags no gross profit of its own..

PeriodEndingGross Profit
Q2 '262026-06-30265.2M
Q1 '262026-03-31243.1M
Q4 '252025-12-31195.4M
Q3 '252025-09-30154.4M
Q2 '252025-06-30447.9M
Q1 '252025-03-31130.1M
Q4 '242024-12-31222.7M
Q3 '242024-09-30132.7M
Q2 '242024-06-30221.1M
Q1 '242024-03-31117.3M
Q4 '232023-12-31321.4M
Q3 '232023-09-30142M
Q2 '232023-06-30185.9M
Q1 '232023-03-31129.2M
Q4 '222022-12-31148.2M
Q3 '222022-09-30158.3M
Q2 '222022-06-30129M
Q1 '222022-03-31137.7M
Q4 '212021-12-31437.8M
Q3 '212021-09-30130M

Operating Income Quarterly

PeriodEndingOperating Income
Q2 '262026-06-30-102.3M
Q1 '262026-03-31-117.4M
Q4 '252025-12-31-214.5M
Q3 '252025-09-30-160.2M
Q2 '252025-06-30139.8M
Q1 '252025-03-31-146.9M
Q4 '242024-12-31-110.8M
Q3 '242024-09-30-148.7M
Q2 '242024-06-30-66.1M
Q1 '242024-03-31-149.5M
Q4 '232023-12-31-6.1M
Q3 '232023-09-30-143.3M
Q2 '232023-06-30-90.2M
Q1 '232023-03-31-114.1M
Q4 '222022-12-31-208M
Q3 '222022-09-30-59.2M
Q2 '222022-06-30-85.5M
Q1 '222022-03-31-57.5M
Q4 '212021-12-31220.6M
Q3 '212021-09-30-85.8M

Net Income Quarterly

PeriodEndingNet Income
Q2 '262026-06-30-114.6M
Q1 '262026-03-31-92.5M
Q4 '252025-12-31-229.4M
Q3 '252025-09-30-128.6M
Q2 '252025-06-30123.6M
Q1 '252025-03-31-146.9M
Q4 '242024-12-31-104.3M
Q3 '242024-09-30-140.5M
Q2 '242024-06-30-66.3M
Q1 '242024-03-31-142.8M
Q4 '232023-12-31-9.3M
Q3 '232023-09-30-147.4M
Q2 '232023-06-30-85.3M
Q1 '232023-03-31-124.3M
Q4 '222022-12-31-52.4M
Q3 '222022-09-30-47M
Q2 '222022-06-30-105.1M
Q1 '222022-03-31-65.2M
Q4 '212021-12-31224.6M
Q3 '212021-09-30-82.5M

Cost of Revenue Quarterly

PeriodEndingCost of Revenue
Q2 '262026-06-302.7M
Q1 '262026-03-313M
Q4 '252025-12-318M
Q3 '252025-09-302.3M
Q2 '252025-06-304.2M
Q1 '252025-03-311.5M
Q4 '242024-12-313.8M
Q3 '242024-09-301.1M
Q2 '242024-06-304.2M
Q1 '242024-03-312.2M
Q4 '232023-12-313.1M
Q3 '232023-09-302.2M
Q2 '232023-06-302.5M
Q1 '232023-03-311.3M
Q4 '222022-12-313.7M
Q3 '222022-09-301.5M
Q2 '222022-06-304.7M
Q1 '222022-03-314.2M
Q4 '212021-12-312.2M
Q3 '212021-09-303.1M

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q2 '262026-06-30565.5M
Q1 '262026-03-31-792.8M
Q4 '252025-12-31-137.7M
Q3 '252025-09-30-131.4M
Q2 '252025-06-30151.3M
Q1 '252025-03-31-150.8M
Q4 '242024-12-31-116.1M
Q3 '242024-09-30-115M
Q2 '242024-06-30-119.9M
Q1 '242024-03-31-149.9M
Q4 '232023-12-3132.9M
Q3 '232023-09-30-109M
Q2 '232023-06-30-97.4M
Q1 '232023-03-31-134M
Q4 '222022-12-31-200.2M
Q3 '222022-09-30-24.4M
Q2 '222022-06-30-18.1M
Q1 '222022-03-31-31.6M
Q4 '212021-12-31203.7M
Q3 '212021-09-30-55.6M

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q2 '262026-06-30549.5M
Q1 '262026-03-31-814.6M
Q4 '252025-12-31-159M
Q3 '252025-09-30-136.7M
Q2 '252025-06-30139M
Q1 '252025-03-31-163.4M
Q4 '242024-12-31-141.6M
Q3 '242024-09-30-124M
Q2 '242024-06-30-126.1M
Q1 '242024-03-31-154.4M
Q4 '232023-12-3132M
Q3 '232023-09-30-111.2M
Q2 '232023-06-30-109.4M
Q1 '232023-03-31-144.5M
Q4 '222022-12-31-204.3M
Q3 '222022-09-30-30M
Q2 '222022-06-30-21.4M
Q1 '222022-03-31-34.4M
Q4 '212021-12-31201.2M
Q3 '212021-09-30-58.9M

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q2 '262026-06-30165.4M
Q1 '262026-03-31164.9M
Q3 '252025-09-30159.8M
Q2 '252025-06-30182.3M
Q1 '252025-03-31158.7M
Q3 '242024-09-30148.6M
Q2 '242024-06-30146M
Q1 '242024-03-31145.5M
Q3 '232023-09-30143.3M
Q2 '232023-06-30143.1M
Q1 '232023-03-31142.7M
Q3 '222022-09-30141.9M
Q2 '222022-06-30141.8M
Q1 '222022-03-31141.6M
Q4 '212021-12-31160.3M
Q3 '212021-09-30141.1M
Q2 '212021-06-30141M
Q1 '212021-03-31140.8M
Q4 '202020-12-31140M
Q3 '202020-09-30139.7M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q2 '262026-06-30-3.46
Q1 '262026-03-31-2.07
Q4 '252025-12-31-2.44
Q3 '252025-09-30-1.69
Q2 '252025-06-30-1.84
Q1 '252025-03-31-2.99
Q4 '242024-12-31-3.04
Q3 '242024-09-30-2.44
Q2 '242024-06-30-2.52
Q1 '242024-03-31-2.67
Q4 '232023-12-31-2.56
Q3 '232023-09-30-2.87
Q2 '232023-06-30-2.17
Q1 '232023-03-31-2.31
Q4 '222022-12-31-1.90
Q3 '222022-09-30-0.12
Q2 '222022-06-30-0.37
Q1 '222022-03-31-0.20
Q4 '212021-12-31-0.38
Q3 '212021-09-30-4.33